November 2023 Medical News Summary

<p>Why Physicians Don’t Deprescribe Medicines; What to Know About Wegovy’s Rare but Serious Adverse Effects; What to Know About Zepbound, the Newest Antiobesity Drug<br /> <br /> <strong>Related Content:</strong></p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.16620?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging</a></li> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.24539?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management</a></li> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.22245?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Deciding When It’s Better to Deprescribe Medicines Than to Continue Them</a></li> </ul>